Edith Cowan University

Research Online
Research outputs 2014 to 2021
2017

Altered levels of blood proteins in Alzheimer's disease
longitudinal study: Results from Australian Imaging Biomarkers
Lifestyle Study of Ageing cohort
Veer B. Gupta
Edith Cowan University

Eugene Hone
Edith Cowan University

Steve Pedrini
Edith Cowan University

James D. Doecke
Sid E. O'Bryant

See next page for additional authors

Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013
Part of the Neurology Commons
10.1016/j.dadm.2017.04.003
Gupta, V. B., Hone, E., Pedrini, S., Doecke, J., O'Bryant, S., James, I., ... & Masters, C. L. (2017). Altered levels of blood
proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of
Ageing cohort. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 8(1). 60-72.
https://doi.org/10.1016/j.dadm.2017.04.003
This Journal Article is posted at Research Online.
https://ro.ecu.edu.au/ecuworkspost2013/2755

Authors
Veer B. Gupta, Eugene Hone, Steve Pedrini, James D. Doecke, Sid E. O'Bryant, Ian James, Ashley I. Bush,
Christopher C. Rowe, Victor L. Villemagne, David Ames, Colin L. Masters, and Ralph N. Martins

This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworkspost2013/2755

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 8 (2017) 60-72

Blood-Based Biomarkers
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Abstract

Introduction: A blood-based biomarker panel to identify individuals with preclinical Alzheimer’s
disease (AD) would be an inexpensive and accessible first step for routine testing.
Methods: We analyzed 14 biomarkers that have previously been linked to AD in the Australian Imaging Biomarkers lifestyle longitudinal study of aging cohort.
Results: Levels of apolipoprotein J (apoJ) were higher in AD individuals compared with healthy
controls at baseline and 18 months (P 5 .0003) and chemokine-309 (I-309) were increased in AD
patients compared to mild cognitive impaired individuals over 36 months (P 5 .0008).
Discussion: These data suggest that apoJ may have potential in the context of use (COU) of AD diagnostics, I-309 may be specifically useful in the COU of identifying individuals at greatest risk for progressing toward AD. This work takes an initial step toward identifying blood biomarkers with potential
use in the diagnosis and prognosis of AD and should be validated across other prospective cohorts.
Ó 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease
characterized by extracellular deposition of amyloid b (Ab)
in senile plaques and intracellular formation of neurofibrillary
1
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tangles of hyperphosphorylated tau protein. Although a small
percentage of AD patients carry specific mutations that cause
the disease at an earlier age, most patients are considered sporadic with a later age of onset. For this subgroup, the major risk
factor is the ε4 allele of the APOE gene. Currently, the definitive diagnosis of AD can be performed only postmortem with
the analysis of senile plaques in the brain parenchyma,
although positron emission tomography (PET) scan modalities have received regulatory approval that can detect the

http://dx.doi.org/10.1016/j.dadm.2017.04.003
2352-8729/ Ó 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

V.B. Gupta et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 8 (2017) 60-72

presence of Ab among living individuals. Furthermore, the
search for biomarker panels has also been extended to cerebrospinal fluid (CSF) in AD and other neurological diseases [1–3].
It is to note that the examination of CSF, which reflects more
closely what happens in the brain, has the disadvantage that
CSF collection requires trained people, it is associated with
a higher degree of risks, and it is not suitable for repeated
draws. Although PET and CSF biomarkers are currently the
gold standard to detect amyloid living patients, these
biomarkers are expensive and cannot be used in routine
clinical care. Blood-based biomarkers provide cost- and
time-effective methods that can be used as the first step in a
multistage neurodiagnostic process that would significantly
streamline and cost contain this novel strategy. Recent years
have witnessed an exponential increase in the investigation
of blood-based biomarkers that have diagnostic and prognostic
potential in AD. The identification of blood-based biomarkers
that can identify groups that are at a higher risk for AD within
routine clinical care (e.g., within primary care clinics) before
the clinical manifestation would make possible targeted early
treatments aimed at postponing the onset of the clinical disease
itself. Such a paradigm would be advantageous not only for the
individuals at risk, but also for the whole community, as
delaying the onset of the disease would lighten the economic
burden that is associated with the care of these patients.
In the recent years, several groups have published reports
that associate AD to a specific group of biomarkers that
largely focus on (1) discriminating between AD cases and
controls (i.e., putative “context of use” [COU] related to
AD diagnostics) or (2) predict the onset of the disease (i.e.,
putative COU related to AD prognostics). With regards to
diagnostics, Ray et al. [4] defined a group of 18 plasma
biomarkers out of a larger group of 120 analyzed that discriminated AD from controls with high accuracy. Later in 2008,
research based on this 18 biomarker panel found that using
5 of these 18 was sufficient to differentiate between AD and
controls with the same accuracy [5]. However, two subsequent analyses of these 18 proteins in different cohorts [6,7]
failed to validate the biomarker panel finding significant
differences between AD and controls only in five and three
biomarkers, respectively. In 2012, the current group [8] identified a panel of 18 blood-based biomarkers that distinguished
between AD and controls with high accuracy in the AIBL
cohort and replicated the findings in the ADNI cohort. At
the same time, an independent group analyzed two cohorts
(TARC and ADNI) and found a panel of 11 biomarkers that
accurately discriminated AD from controls across both serum
and plasma [9], which was a continuation of their previous
work [10] in which a panel of 30 biomarkers was identified.
Another research group [11] reported that a panel of three
blood-based biomarkers was able to discriminate AD from
controls with a correct classification of more than 80%. In
2012, Johnstone et al. [12] reported a panel of 11 biomarkers
in ADNI cohort identified preclinical AD. Other groups have
performed similar analysis and identified a plasma biomarker
panel in AD [13]. Some other studies have also associated
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blood-based biomarker panels with microvascular pathology,
brain atrophy, and cognitive decline in AD [14,15]. The
common problem in all these studies is the variability of the
biomarkers evaluated and the statistical analysis used to
determine the diagnostic and prognostic value of the panel
for AD with sufficient sensitivity and specificity. In this
study, a panel of 14 biomarkers that have been identified as
significant in 1 or more of the previous analyses was
selected for analysis using the well-characterized AIBL
cohort, baseline and longitudinal samples. These analyses
were undertaken with the goal of determining if biomarker
levels were different in AD compared with healthy controls
(HCs) and mild cognitive impairment across time points,
hence demonstrating their diagnostic value. In addition, if
these biomarkers were associated with brain Ab burden as
assessed by PET results suggesting that different levels may
be able to predict which individuals will convert to MCI/
AD. The longitudinal analysis in AD patients was also carried
out to study whether these biomarkers were associated with
the progression of the disease.

2. Materials and methods
2.1. Population sample
2.1.1. The AIBL cohort
The cohort recruitment process including the neuropsychological, lifestyle, and mood assessments have been previously described in detail [16]. In brief, the AIBL study
recruited a total of 1166 participants over the age of 60 years
at baseline, of whom 54 were excluded because of comorbid
disorders or consent withdrawal. Using the NINCDS-ARDA
international criteria for AD diagnosis [17] and symptomatic
predementia phase criteria for MCI diagnosis [18], a clinical
review panel determined disease classifications at each
assessment time point to ensure accurate and consistent
diagnoses among the participants. According to these
diagnostic criteria, participants were classified into one of
three groups; AD, MCI, or HCs. At baseline, there were a
total of 768 HCs, 133 MCI, and 211 AD subjects.
The AIBL study is a prospective, longitudinal study,
following participants at 18-month intervals. This particular
study reports on 711 individuals who completed the full
study assessment and corresponding blood sample collection
at baseline, 18 months and 36 months follow-up time points.
The institutional ethics committees of Austin Health, St.
Vincent’s Health, Hollywood Private Hospital, and Edith
Cowan University granted ethics approval for the AIBL
study. All volunteers gave written informed consent before
participating in the study.
2.1.2. Sample collection and APOE genotyping
Plasma was isolated from whole blood and collected in
standard EDTA tubes with prostaglandin E1 (33.3 ng/mL,
Sapphire Biosciences, NSW, Australia) added. On
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completion of blood fractionation, samples were aliquoted
and immediately stored in liquid nitrogen until required for
analysis. DNA was isolated from whole blood using a
QIAamp DNA Blood Midi Kit (Qiagen, VIC, Australia) according to the manufacturer’s protocol, and APOE genotype
was determined through either polymerase chain reaction
(PCR) amplification and restriction enzyme digestions, as
previously described [19], or through TaqMan genotyping
assays (Life Technologies, Mulgrave, VIC, Australia) for
rs7412 (assay ID: C____904973_10) and rs429358 (assay
ID: C___3084793_20). For TaqMan assays, PCRs and realtime fluorescence measurements were carried out on a
ViiAÔ 7 real-time PCR system (Applied Biosystems, VIC,
Australia) using the TaqMan GTXpress Master Mix (Life
Technologies) methodology per manufacturer’s instructions.
2.1.3. Plasma biomarker assay
Aliquots were prepared according to the volume required
for each set of assays and stored at 280 C. All samples were
assayed in duplicate via a multiplex biomarker assay platform using ECL on the SECTOR Imager 2400A from
Meso Scale Discovery (MSD; http://www.mesoscale.com).
The analytes requiring similar dilution were grouped
together in the multiplexing plate by the manufacturer.
The MSD platform has been used extensively to assay biomarkers associated with a range of human diseases including
AD. ECL measures have well-established properties of
being more sensitive and requiring less sample volume
than conventional enzyme-linked immunosorbent assay,
the gold standard for most assays. The biomarkers assayed
were chosen from previously generated and crossvalidated AD algorithms from various biomarker studies
[8–10,20] and included the following: thrombopoietin
(TPO), interleukin-18 (IL-18), fatty acid binding protein
(FABP3), pancreatic polypeptide Y (PPY), chemokine
I309 (I309), serum amyloid A (SAA), C-reactive protein
(CRP), soluble vascular adhesion molecule 1 (sVCAM1),
soluble intercellular adhesion molecule 1 (sICAM1),
alpha-2-macroglobulin (A2M), beta-2 microglobulin
(B2M), Factor VII (FVII), adiponectin (adipo), apolipoprotein J (apoJ).
Plates were washed and blocked as per manufacturer
instructions using the supplied buffers. Samples were diluted
according to each respective assay group and applied to the
plate, along with standards. Plates were then sealed and
incubated at room temperature for 2 hours. Plates were
washed three times using phosphate buffered saline Tween
20 (PBST), then secondary detection antibodies were added
and plates were sealed and incubated for a further hour.
Plates were washed three times with PBST and read solution
was added according to the assay instructions. Plates were
immediately read using an MSD plate reader. The supplied
software was used to determine standard curve and sample
concentration, according to 5-PL curve-fitting techniques.
The final protein biomarker concentration was reported in
pg/mL units.

2.1.4. Assessment of neocortical Ab via PiB-PET
A subset of the AIBL cohort (n 5 287) underwent carbon
11-labeled Pittsburgh compound B–positron emission
tomography (11C-PiB-PET) imaging at baseline to measure
brain Ab burden, as previously described [21]. PET standardized uptake value (SUV) data were summed and normalized
to the cerebellar cortex SUV values to obtain the region to
cerebellar ratio (standardized uptake value ratio [SUVR]).
A threshold of 1.5 SUVR was used to discriminate between
high (PiB1) and low (PiB2) brain Ab burden [22]. Of the
total 711 participants reported on here, 180 individuals
underwent PiB-PET imaging at baseline, 158 at 18-month
follow-up, and 120 underwent at 36-month follow-up.
2.1.5. Statistical methodology
Descriptive statistics including means, standard deviations, and frequencies were calculated across clinical classifications. Gender and APOE ε4 allele comparisons were
assessed using chi squared (c2) test and Fisher’s exact test
where necessary. Analysis of mean biomarker levels
between clinical classifications adjusted for age, gender,
and APOE ε4 allele status to assess the potential of these
proteins as biomarkers for AD was performed using
proportional odds logistic regression (for three group analyses, HC/MCI/AD as the outcome) and generalized linear
modeling (GLM, for two groups, HC vs. AD as the outcome,
binomial family). These statistical models were used as they
are able to assess the differences in mean biomarker levels,
adjusted for confounders under the assumption that there
is a certain level of uncertainty in the outcome (clinical classification is not 100% correct). P-values were compared a
Bonferroni adjusted alpha (a), with the number of biomarkers tested as the adjustment factor (a 5 0.05/14,
0.00036).
For the longitudinal analyses, linear mixed-effects
modeling (LMM, using the biomarker as the [Gaussian]
outcome at each time point) was used to assess mean
biomarker levels over time for stable HC and AD groups
individually, adjusted for age, gender, site, and APOE ε4
allele status. Assessment of biomarkers longitudinally
between HC/MCI and AD groups was performed using
cumulative link mixed models (CLMMs) for the three group
clinical classification comparison, and the generalized linear
mixed models (GLMMs, binomial family) for the individual
group comparisons. GLM combined with receiver operating
characteristic (ROC) analyses were combined to perform
100-fold repeated random subsampling validation for
disease predictions.
Correlations between quantitative SUVR and all the biomarkers were carried out using Spearman’s rank correlation
analysis (r). A cutoff value of 1.5 for SUVR was used as the
most appropriate criterion for biomarker evaluation. The R
statistical software environment, version 2.15 was used for
all statistical analyses (Team, R Development Core. 2009.
R: A Language and Environment for Statistical Computing
Manual).
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still showed differences between comparative groups; however, these were only significant at the nominal significance
level (without Bonferroni correction, a 5 0.05, Table 2).

3. Results
3.1. Population demographics
Baseline, 18-month, and 36-month follow-up time points
demographic data, APOE ε4 allele status, and Mini–Mental
State Examination (MMSE) for the AIBL cohort are presented in Table 1. PiB-SUVRs for the AIBL imaging subcohort are also presented in Table 1. Plasma levels of
biomarkers (pg/mL) TPO, IL-18, FABP3, PPY, I309, SAA,
CRP, sVCAM1, sICAM1, A2M, B2M, FVII, adipo, apoJ
were assayed in 554 healthy controls, 65 participants with
MCI, and 92 participants with AD (total N 5 711 at baseline). Age, APOE ε4 allele status, and MMSE were significantly different between clinical classifications at baseline,
18 months, and 36 months (P , .0001). There was no difference in the proportion of females to males at either time
point (P . .05). Total number of participants from the
AIBL imaging subcohort was lower compared with the total
group. PiB-SUVR was significantly higher in the MCI and
AD groups compared with the HC group (P , .0001).

3.3. Comparison of mean biomarker levels between HC
and AD groups over 36 months
Assessing mean biomarker levels over time between clinical classifications (three groups, CLMM), adjusted for age,
gender, site, and APOE ε4 allele status, strongest associations were seen for I309 (P 5 .01), sVCAM (P 5 .04),
B2M (P 5 .02), and ApoJ (P 5 .01), although none of these
reached the Bonferroni corrected threshold. Conducting
pairwise comparisons over time (GLMM), levels of I309
were significantly increased in AD participants compared
with MCI participants over time (P 5 .00076). Before
adjustment for covariates, levels of PPY were also higher
in AD participants compared with MCI participants over
time (P 5 .009).
3.4. Biomarker trends over time for HC and AD groups

3.2. Association of biomarkers between clinical
classification at the time of collection
Comparing biomarker levels between HC and MCI
groups before adjustment for cofounders, FABP3 was significantly higher at both baseline (P 5 .00002) and 18-month
(P 5 .0001) time points, but not at 36 months (P 5 .0096)
(Table 2). This significance however was abrogated after adjusting for age, gender, and APOE ε4 allele status. For the
MCI versus AD group comparison, PPY stood out at
18 months, with significantly higher levels in AD compared
with MCI participants, even after adjustment for both confounders and multiple testing (P 5 .0001). Comparing
biomarker levels between HC and AD groups across the
three time points, 7 of 14 biomarkers measured were significantly higher in AD compared to HC at baseline and
18 months, and six biomarkers were significantly higher at
36 months. After adjustment for confounders, apoJ at baseline and at 18 months was marginally significant after adjustment for multiple comparisons (P 5 .0004). Those
associations that were not replicated at multiple time points

To assess biomarker levels over time, stratified data (two
groups; only those that remained either HC (N 5 590) or
AD (N 5 109) over 36 months [stable groups]) were assessed, adjusted for covariates age, gender, site, and APOE
ε4 allele status using LMM. TPO levels were significantly
decreased for the HC group (B 5 20.03 6 0.005,
P , .0001), but not for the AD (B 5 20.02 6 0.01,
P 5 .332); however, the slope was similar. CRP levels for
HC decreased (B 5 20.05 6 0.02, P 5 .05), whereas for
the AD group, they increased, albeit this was not significant
(B 5 0.14 6 0.08, P 5 .09). sVCAM1 levels in the AD
group increased over time (B 5 0.03 6 0.01, P 5 .02); however, this was not seen for the HC group (B 5 0.001 6 0.004,
P 5 .73). For IL-18, the decrease in biomarker levels
over time was slightly stronger for the HC group
(B 5 20.03 6 0.006, P 5 .0002) compared with the AD
group (B 5 20.02 6 0.02, P 5 .18). Both A2M and B2M
increased over time in HC and AD groups; however, rates
were slightly different, with HC mean levels for A2M
increasing more than that for the AD group (HC:

Table 1
Demographic characteristics
Baseline

N
Age (mean SD)
Gender (F/M)
APOE ε4 (2ve/1ve)
MMSE (median IQR)
SUVR (N)
SUVR (mean SD)

18 months

36 months

HC

MCI

AD

HC

MCI

AD

HC

MCI

AD

554
69.79 (6.51)
330/224
401/153
29 (2)
127
1.36 (0.38)

65
74.84 (7.54)
36/29
32/33
27 (3)
32
2.02 (0.57)

92
77.01 (7.43)
52/40
28/64
21 (4.25)
21
2.29 (0.5)

543
71.12 (6.34)
328/215
395/148
29 (2)
116
1.35 (0.37)

51
76.05 (7.28)
23/28
32/19
27 (3)
19
2.03 (0.63)

116
78.68 (7.63)
67/49
34/82
19 (8)
23
2.32 (1.35)

526
72.65 (6.26)
318/208
387/139
29 (2)
95
1.38 (0.37)

50
77.56 (7.47)
25/25
29/21
26.5 (3)
18
1.8 (0.65)

129
80.41 (7.39)
73/56
41/88
16 (10)
24
2.43 (0.53)

P-values
,.0001
..05
,.0001
,.0001
,.0001

Abbreviations: HC, healthy control; MCI, mild cognitive impairment; AD, Alzheimer’s disease; SD, standard deviation; MMSE, Mini–Mental State Examination; IQR, interquartile range; SUVR, standardized uptake value ratio.
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Table 2
Cross-sectional comparisons across three clinical classifications namely HC, MCI, and AD
Mean (SD)

Baseline

18 months

36 months

TPO
IL-18
FABP3
PPY
I309
SAA
CRP
sVCAM
sICAM
A2M
B2M
fVII
Adipo
ApoJ
TPO
IL-18
FABP3
PPY
I309
SAA
CRP
sVCAM
sICAM
A2M
B2M
fVII
Adipo
ApoJ
TPO
IL-18
FABP3
PPY
I309
SAA
CRP
sVCAM
sICAM
A2M
B2M
fVII
Adipo
ApoJ

MCI

AD

453.72 (128.25)
486.4 (133.06)
498.25 (151.94)
201.62 (78.55)
202.11 (99.01)
205.86 (102.95)
6417.9 (2498.74)
7664.95 (2577.08)
7707.77 (2993.31)
151.51 (123.25)
195.11 (190.74)
226.44 (153.94)
1.76 (0.89)
1.66 (0.66)
2.25 (1.43)
5,014,328.58 (12,441,294.73)
4,556,617.17 (5,400,336.74)
10,066,848.34 (25,001,707.84)
2,623,075.41 (5,483,161.45)
2,105,933.51 (1,992,259.53)
2,764,309.64 (5,501,614.76)
412,578.76 (93,418.88)
443,844.82 (107,111.58)
464,594.39 (118,439.3)
258,715.61 (57,091.32)
274,167.46 (70,100.74)
275,757.24 (57,768.89)
1,747,511,738.03 (513,469,652)
1,855,714,846.34 (602,037,583.95) 1,893,399,396.14 (581,856,370.49)
2,302,005.26 (854,220.32)
2,564,836.72 (962,444.25)
2,600,875.68 (868,669.09)
855,774.28 (204,030.04)
879,676.06 (200,143.09)
870,519.29 (211,777.27)
72,058,918.21 (37,972,553.53)
85,795,000.94 (47,271,598.65)
91,367,246.13 (52,484,686.66)
34,840,490.7 (6,569,730.63)
36,905,488.48 (7,081,682.5)
38,901,971.01 (8,064,135.24)
439.01 (124.56)
484.25 (130.48)
489.65 (168.28)
197.31 (78.42)
202.49 (92.26)
201.59 (101.17)
6560.26 (2371.26)
7983.14 (2970.32)
7921.63 (3075.55)
160.98 (124.66)
164.33 (162.1)
231.27 (157.33)
1.82 (1.04)
1.72 (0.91)
2.25 (1.28)
4,508,476.82 (10,011,818.68)
6,010,980.54 (13,928,739.6)
11,051,022.73 (26,601,726.7)
2,324,026.89 (3,678,293.91)
3,244,249.76 (7,168,549.06)
3,750,314.02 (9,648,464.51)
413,866.28 (94,396.07)
451,372.28 (128,980.99)
461,761.39 (123,431.77)
256,940.34 (63,741.88)
276,181.68 (81,976.23)
273,854.69 (65,996.05)
1,799,156,641.14 (533,559,105.75) 1,818,415,510.22 (540,494,569.01) 1,966,783,241.78 (593,726,925.78)
2,380,739.82 (906,482.97)
2,586,551.41 (1,058,022.97)
2,792,433.32 (1,002,092.54)
859,839.14 (217,735.63)
843,890.76 (211,518.29)
904,916.05 (221,993.04)
73,899,317.71 (40,137,703.56)
87,609,586.8 (51,060,964.01)
89,456,380.55 (47,630,520.81)
35,076,852.22 (6,760,610.92)
36,935,240.02 (7,250,908.7)
39,828,311.84 (8,650,920.67)
437.79 (119.73)
463.2 (105.38)
478.3 (153.32)
194.68 (77.96)
199.61 (97.69)
194.57 (94.75)
6953.36 (2904.37)
7988.9 (3178.54)
8026.43 (3242.37)
162.11 (118.95)
172.88 (151.87)
228.83 (165.22)
1.91 (1.12)
1.72 (0.89)
2.29 (1.41)
6,591,850.97 (20,102,101.96)
6,152,281.83 (9,696,054.8)
11,689,850.22 (28,348,629.61)
2,815,106.56 (6,320,376.91)
2,580,568.27 (3,838,300.23)
4,135,642.49 (10,667,549.77)
427,124.68 (103,231.67)
458,365.34 (108,775.08)
493,257.79 (138,934.86)
264,728.18 (65,030.13)
273,235.93 (73,269.22)
290,037.45 (80,897.55)
1,827,578,796.9 (545,505,679.48) 1,778,523,439.16 (433,650,399.82) 1,981,649,902.93 (624,365,511.97)
2,449,111.13 (900,460.4)
2,776,486.26 (1,441,411.42)
2,869,544.1 (1,083,739.71)
859,473.47 (211,784.3)
828,173.72 (239,319.27)
920,802.51 (236,389.85)
76,652,983.41 (42,470,109.59)
95,692,502.42 (128,009,842.11)
91,388,867.36 (48,296,710.64)
35,855,560.96 (6,862,794.16)
36,925,546.32 (7,663,254.78)
39,890,373.94 (8,623,166.76)

HC versus MCI

HC versus AD

MCI versus AD

Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
0.0012
0.9283
2.02E208
3.16E205
0.0015
0.019
0.1497
7.59E206
0.0046
0.0062
6.45E205
0.33
9.37E206
2.70E207
0.0005
0.9834
3.03E209
3.65E205
0.0021
0.0049
0.2513
3.82E205
0.0086
0.0051
2.00E206
0.1079
2.76E205
3.59E209
0.0012
0.7527
1.14E205
0.0004
0.0054
0.0022
0.2797
1.67E207
0.0017
0.1339
5.85E205
0.4943
0.0017
0.0027

0.0356
0.8336
0.3356
0.1075
0.2862
0.0582
0.9508
0.1634
0.1765
0.4693
0.6796
0.4349
0.0461
0.0003
0.0172
0.9396
0.2022
0.0443
0.9447
0.0331
0.5808
0.5612
0.629
0.6885
0.4936
0.094
0.0681
0.0003
0.1789
0.876
0.6319
0.2124
0.5469
0.0106
0.9952
0.0134
0.1356
0.6535
0.1774
0.5917
0.2182
0.0448

0.0563
0.8567
2.18E205
0.1249
0.5181
0.2092
0.905
0.012
0.0524
0.1635
0.0223
0.3435
0.0067
0.0183
0.0176
0.8507
0.0001
0.4921
0.369
0.8312
0.8488
0.0336
0.07
0.7756
0.1107
0.636
0.0197
0.0635
0.1478
0.8155
0.0096
0.7835
0.1233
0.3237
0.6139
0.0351
0.406
0.4509
0.1267
0.3422
0.4015
0.6585

0.2509
0.7213
0.1285
0.9325
0.117
0.2693
0.5195
0.3654
0.3084
0.8476
0.7112
0.3465
0.0898
0.0875
0.0276
0.5852
0.1219
0.0557
0.0669
0.8133
0.9327
0.6051
0.3302
0.5794
0.754
0.9626
0.0158
0.1112
0.6842
0.5699
0.7746
0.1079
0.0118
0.1837
0.9748
0.2046
0.624
0.2519
0.4804
0.3441
0.358
0.752

0.0039
0.9954
3.41E206
7.56E206
1.13E205
0.0319
0.059
4.09E205
0.0165
0.0101
0.0002
0.5341
9.60E205
4.31E207
0.0034
0.9475
5.15E208
1.44E207
0.0001
0.0007
0.2133
0.0001
0.022
0.002
1.18E206
0.0399
0.0001
7.05E210
0.0023
0.6417
0.0001
2.56E205
0.0001
0.0018
0.3071
1.60E207
0.001
0.0359
4.51E205
0.2094
4.92E205
0.001

0.0502
0.8138
0.8375
0.037
0.0167
0.1127
0.4626
0.0855
0.6791
0.4797
0.283
0.8441
0.0402
0.0004
0.0836
0.8877
0.4821
0.01
0.1752
0.007
0.5945
0.5823
0.8845
0.4514
0.1792
0.275
0.0711
0.0004
0.4755
0.7694
0.4757
0.0651
0.5706
0.016
0.9831
0.0136
0.3142
0.6007
0.1172
0.4345
0.0149
0.0456

0.5974
0.8969
0.9936
0.0775
0.001
0.6153
0.1728
0.3422
0.8869
0.5236
0.5081
0.7428
0.5956
0.1232
0.8974
0.86
0.8588
0.0002
0.0028
0.0519
0.5862
0.5645
0.8916
0.097
0.1148
0.0974
0.7607
0.0451
0.5599
0.6611
0.8671
0.0111
0.0007
0.3668
0.8702
0.1919
0.2503
0.0396
0.25
0.1037
0.0003
0.0799

0.5387
0.5814
0.4419
0.1454
0.0066
0.6228
0.4252
0.7705
0.9136
0.4959
0.975
0.6244
0.9282
0.1435
0.4575
0.4857
0.8237
0.0001
0.0202
0.2179
0.9336
0.8394
0.5686
0.1402
0.3201
0.3038
0.399
0.523
0.3682
0.4462
0.5791
0.0119
0.0266
0.8677
0.8581
0.6776
0.5674
0.1643
0.5588
0.0791
0.0246
0.0771

Abbreviations: HC, healthy control; MCI, mild cognitive impairment; AD, Alzheimer’s disease; SD, standard deviation; TPO, thrombopoietin; IL-18, interleukin-18; FABP3, fatty acid binding protein;
PPY, pancreatic polypeptide Y; I309, chemokine I309; SAA, serum amyloid A; CRP, C-reactive protein; sVCAM, soluble vascular adhesion molecule; sICAM, soluble intercellular adhesion molecule; A2M,
alpha-2-macroglobulin; B2M, beta-2 microglobulin; FVII, Factor VII; adipo, adiponectin; apoJ, apolipoprotein J.
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Time point Biomarker HC

HC/MCI/AD
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B 5 0.008 6 0.004, P 5 .03; AD: B 5 0.006 6 0.01,
P 5 .57), while the mean AD levels for B2M increased
more than that for the HC group (HC: B 5 0.001 6 0.001,
P 5 .81; AD: B 5 0.03 6 0.01, P 5 .05).
3.5. Capability of a combined biomarker model to
diagnose AD
To assess the diagnostic capability of the strongest biomarkers for AD at each time point (found via stepwise
modeling), an ROC analysis was performed after building
a generalized linear model using APOE ε4 allele status,
age, sVCAM1, PPY, I309, apoJ, SAA, and CRP (main
effects model only) with dependent variable HC (set as 0)
and AD (set as 1). Training the model using a random
70% of the data, and testing the model on the remaining
30%, and iterating through this 100 times enabled crossvalidated prediction estimates of approximately 78%–79%
sensitivity and specificity, and AUC values at approximately
85% for all three time points. Repeating this with age,
gender, and APOE ε4 allele status only, sensitivity, specificity, and AUC values were approximately 77%, 77%, and
83%, respectively.
3.6. Cross-sectional differences between transitional,
nontransitional, and stable AD
We further grouped AIBL study participants based on the
change in clinical classification over 36 months [23]. Participants were classified into three groups: (1) those HC that did
not transition (nontransition), (2) those who transitioned
from either HC or MCI to either MCI or AD, including
MCI participants (transition), and (3) stable AD participants
(stable AD) over the 36-month period (Table 3). Because
transitions were classed as change from baseline, statistics
from baseline are not shown. Table 4 summarizes the
cross-sectional differences in the levels of biomarkers
between different categories.
Before adjustment for confounders, biomarkers such as
PPY, I309, and B2M were able to significantly differentiate
(P , .00036) between nontransitional and stable AD
categories at both 18- and 36-month time points. At the
18-month but not at the 36-month time point, FABP3 and
apoJ were able to differentiate between nontransitional and
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stable AD (P , .00036). At the 36-month but not at the
18-month time point, SAA and sVCAM were able to differentiate between nontransitional and stable AD (P , .00036).
None of these associations were statistically significant after
adjustment for age, gender, and APOE ε4 allele status.
Finally, apoJ was significantly increased in the stable AD
group compared with the nontransition group at 18 months,
both before and after adjustment for confounders
(P , .00036).
Comparing biomarker levels between nontransition and
transition groups at both 18- and 36-month time points,
FABP3 and sVCAM were significantly increased in the transition groups over the nontransition groups (P ,.00036), but
only before adjustment for confounders. Adipo and PPY
were also significantly increased at the 18-month time point
in the transition group (P , .00036) compared with the
nontransition group, but only before adjustment for
confounders. Those associations that were not replicated at
multiple time points still showed differences between
comparative groups; however, these were only significant
at the nominal significance level (without Bonferroni
correction, a 5 0.05, Table 4).
3.7. Correlation with SUVR
Associations of biomarker levels with quantitative SUVR
were assessed among the participants who underwent
PiB-PET at all three collection time points showing weakto-moderate associations. Table 5 shows the correlation coefficients (r values) from correlation analyses between SUVR
and each protein, at baseline, 18 and 36 months. There were
correlations for TPO (BL, 18M), FABP3 (BL, 18M), PPY
(BL, 18M), I309 (BL), B2M (BL), adipo (18M, 36M),
A2M (36M), and apoJ (36M) with SUVR within the MCI
subgroup. Within AD group, correlation with SUVR was
observed for FABP3 (36M) and apoJ (18M).
4. Discussion
AD is characterized by a series of pathological events.
These include amyloid b (Ab) and tau protein deposition,
oxidative damage, and inflammation, resulting in neuronal
cell death and symptoms of cognitive dysfunction. For

Table 3
Demographics table showing participants in three classifications namely nontransition, transition, and stable AD groups
18 months

N
Age (mean SD)
Gender (F/M)
APOE ε4 (2ve/1ve)
MMSE (median SD)
SUVR (N)
SUVR (mean SD)

36 months

P-values

Nontransition

Stable AD

Transition

Nontransition

Stable AD

Transition

520
70.93 (6.23)
314/206
375/145
29 (1.33)
110
1.35 (0.36)

80
78.64 (7.63)
46/34
23/57
19 (5.73)
14
2.26 (0.52)

79
76.6 (7.62)
41/38
40/39
26 (3.21)
29
2.1 (1.35)

504
72.48 (6.14)
305/199
366/138
29 (1.18)
93
1.39 (0.37)

78
80.75 (7.24)
45/33
23/55
14 (7.16)
9
2.29 (0.55)

91
78.09 (7.67)
49/42
45/46
25 (4.79)
33
2.07 (0.68)

18 months

36 months

,.0001
.344
,.0001
,.0001

,.0001
.469
,.0001
,.0001

1.18E218

8.64E213

Abbreviations: AD, Alzheimer’s disease; SD, standard deviation; MMSE, Mini–Mental State Examination; SUVR, standardized uptake value ratio.

66

Mean (SD)
Biomarker Time point Nontransition
TPO
IL-18
FABP3
PPY
I309
SAA
CRP
sVCAM
sICAM
A2M
B2M
fVII
Adipo
ApoJ
TPO
IL-18
FABP3
PPY
I309
SAA
CRP
sVCAM
sICAM
A2M
B2M
fVII
Adipo
ApoJ

18 months
18 months
18 months
18 months
18 months
18 months
18 months
18 months
18 months
18 months
18 months
18 months
18 months
18 months
36 months
36 months
36 months
36 months
36 months
36 months
36 months
36 months
36 months
36 months
36 months
36 months
36 months
36 months

Nontransitional versus
stable AD

Nontransition versus
transition

Unadjusted Adjusted

Unadjusted Adjusted

Unadjusted Adjusted Unadjusted Adjusted

0.001
0.851
2.54E209
0.001
0.037
0.024
0.259
1.39E204
0.013
0.006
5.79E206
0.150
1.36E205
4.58E209
0.009
0.792
5.49E205
0.006
0.145
0.007
0.326
5.53E206
0.004
0.133
9.75E205
0.524
0.001
0.003

0.003
0.848
4.66E206
1.59E206
1.16E204
0.005
0.078
0.001
0.040
0.006
1.83E205
0.127
0.002
1.11E209
0.015
0.453
0.006
1.10E204
1.10E204
1.80E204
0.979
5.85E207
0.003
0.030
1.34E204
0.242
1.76E204
0.015

0.001
0.843
5.04E210
1.89E204
0.011
0.012
0.196
5.73E205
0.011
0.310
0.012
0.639
1.61E204
0.012
0.005
0.714
5.38E205
0.002
0.047
0.002
0.382
4.81E207
0.002
0.929
0.038
0.760
0.212
0.048

All groups
Stable AD

Transition

734,927.17 (915,001.31)
1,213,129.15 (1,769,353.4)
892,786.19 (910,036.55)
785,441.3 (882,205.56)
941,067.44 (1,499,137.36)
864,354.28 (1,182,220.84)
656,531.23 (650,406.72)
1,216,359.82 (1,600,944.1)
1,210,246.46 (1,189,060.66)
754,884.28 (942,461.94)
1,100,224.7 (863,039.37)
933,822.1 (1,500,440.09)
745,631.85 (889,056.6)
1,177,579.61 (1,258,715.97)
742,981.38 (861,920.76)
725,269.34 (856,747.47)
1,220,882.21 (1,766,987.01)
892,634.17 (1,079,246.36)
802,298.22 (1,013,351.45)
756,708.33 (1,093,736.16)
931,625.38 (1,460,346.78)
692,349.99 (783,842.15)
1,089,117.41 (1,411,766.29)
970,385 (1,438,177.48)
715,202.24 (925,269.56)
954,110.77 (1,174,231.67)
955,533.97 (1,243,870.25)
1,799,650,345.22 (534,498,021.57) 1,976,590,545.15 (633,002,758.16) 1,847,123,591.56 (500,192,450.05)
2,381,850.43 (907,635.57)
2,765,830.14 (965,757.82)
2,658,577.56 (1,076,595.34)
860,000.98 (217,912.04)
896,958.07 (219,752.27)
871,258.44 (219,811.81)
73,569,851.3 (39,896,168.21)
88,122,933.79 (49,723,473.27)
91,055,858.46 (47,752,718.81)
35,079,670.75 (6,775,600.88)
40,217,838.62 (8,576,304.99)
37,220,101.86 (7,678,193.84)
703,881.17 (822,936.35)
1,077,448.34 (1,296,890.2)
788,618.72 (667,868.9)
746,645.04 (858,530.23)
810,618.65 (1,376,366.07)
838,000.74 (1,111,612.79)
822,703.27 (1,049,183.88)
981,094.25 (933,201.02)
1,201,488.19 (1,363,089.1)
781,974.64 (989,104.79)
1,151,973.57 (1,092,561.08)
954,990.77 (1,174,520.34)
838,533.81 (1,078,746.36)
1,353,072.01 (1,746,175.95)
804,245.28 (931,700.18)
767,652.82 (800,384.12)
1,345,618.34 (1,628,667.49)
981,199.98 (1,443,722.11)
814,023.99 (954,192.13)
1,026,815.36 (1,628,202.09)
743,721.04 (864,164.17)
792,271.17 (881,653.84)
1,384,448.99 (1,597,444.07)
1,030,504.74 (1,333,138.23)
810,655.53 (993,834.31)
1,252,178.56 (1,731,630.77)
1,025,007.5 (1,135,948.28)
1,829,309,760.37 (546,555,071.17) 1,994,538,938.13 (671,081,010.33) 1,846,566,354.11 (471,139,174.28)
2,449,468.3 (902,701.5)
2,906,874.61 (1,081,026.87)
2,732,263.3 (1,245,439.21)
858,762.71 (211,954.37)
908,875.33 (231,706.93)
888,053.93 (244,355.77)
76,456,574.56 (42,427,744.89)
89,827,129.94 (50,476,152.8)
96,095,398.58 (98,293,155.58)
35,837,220.52 (6,875,230.87)
40,429,122.93 (8,704,482.98)
37,761,901.99 (7,900,428.96)

0.008
0.780
0.089
0.645
0.307
0.132
0.715
0.695
0.720
0.611
0.598
0.197
0.046
2.54E204
0.264
0.951
0.855
0.603
0.071
0.032
0.893
0.118
0.431
0.671
0.181
0.574
0.096
0.061

0.031
0.703
0.609
0.012
0.132
0.012
0.383
0.580
0.758
0.669
0.267
0.553
0.148
2.20E204
0.646
0.691
0.292
0.059
0.235
0.004
0.328
0.005
0.269
0.503
0.125
0.613
0.025
0.205

0.011
0.596
0.108
0.244
0.785
0.038
0.491
0.528
0.732
0.798
0.989
0.431
0.002
0.072
0.499
0.638
0.495
0.445
0.255
0.007
0.887
0.020
0.206
0.366
0.580
0.678
0.443
0.152

Stable AD versus
transition

0.608
0.955
0.732
0.005
0.006
0.230
0.302
0.552
0.880
0.196
0.246
0.452
0.505
0.020
0.583
0.526
0.695
0.046
0.001
0.063
0.416
0.051
0.353
0.059
0.133
0.238
0.023
0.556

0.649
0.647
0.407
0.005
0.026
0.531
0.433
0.973
0.732
0.312
0.500
0.932
0.124
0.151
0.728
0.807
0.338
0.054
0.011
0.327
0.354
0.107
0.473
0.236
0.315
0.182
0.286
0.552

Abbreviations: AD, Alzheimer’s disease; SD, standard deviation; TPO, thrombopoietin; IL-18, interleukin-18; FABP3, fatty acid binding protein; PPY, pancreatic polypeptide Y; I309, chemokine I309; SAA,
serum amyloid A; CRP, C-reactive protein; sVCAM, soluble vascular adhesion molecule; sICAM, soluble intercellular adhesion molecule; A2M, alpha-2-macroglobulin; B2M, beta-2 microglobulin; FVII, Factor
VII; adipo, adiponectin; apoJ, apolipoprotein J.
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Table 4
Cross-sectional differences between transitional, nontransitional, and stable AD group
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Table 5
Correlation between SUVR and protein biomarkers
Biomarker
Baseline
TPO
IL-18
FABP3
PPY
I309
SAA
CRP
sVCAM
sICAM
A2M
B2M
fVII
Adipo
ApoJ
18 months
TPO
IL-18
FABP3
PPY
I309
SAA
CRP
sVCAM
sICAM
A2M
B2M
fVII
Adipo
ApoJ
36 months
TPO
IL-18
FABP3
PPY
I309
SAA
CRP
sVCAM
sICAM
A2M
B2M
fVII
Adipo
ApoJ

All groups

HC

MCI

AD

0.085
0.097
0.186
0.21
0.047
0.065
20.009
0.194
0.159
0.064
0.147
0.068
0.069
0.03

0.039
0.095
0.068
0.116
20.051
0.073
0.019
0.111
0.101
0.063
0.128
0.027
0.016
0.013

0.315
0.086
0.522
0.345
0.354
0.056
20.069
0.272
0.181
0.103
0.237
0.164
0.099
0.01

20.284
0.147
0.242
20.011
20.189
20.021
0.168
20.305
0.053
20.11
20.005
0.167
20.062
20.129

0.103
0.036
0.168
0.179
0.03
20.009
20.087
0.141
0.067
0.011
0.077
20.019
0.082
20.006

0.033
20.02
0.029
0.109
20.025
20.04
20.052
0.041
0.039
20.022
20.005
20.087
0.01
20.026

0.563
0.094
0.434
0.328
0.246
0.07
20.176
0.012
0.094
0.035
0.176
0.211
0.258
20.023

20.264
0.158
0.187
20.11
20.197
0.005
0.091
0.024
20.11
20.191
20.239
20.008
20.167
20.294

0.082
0.067
0.113
0.116
20.004
0.006
20.079
0.158
0.101
20.043
0.004
20.115
0.081
20.005

0.072
0.074
20.012
20.008
20.045
0.039
0.045
0.063
0.132
20.024
0.005
20.097
0.004
20.007

0.066
20.105
0.21
0.197
0.026
20.013
20.079
0.052
20.013
0.235
0
20.279
0.382
20.265

0
0.191
0.399
20.139
0.052
0.069
0.104
0.13
0.095
20.098
0.02
20.163
20.098
20.085

Abbreviations: SUVR, standardized uptake value ratio; HC, healthy
control; MCI, mild cognitive impairment; AD, Alzheimer’s disease;
TPO, thrombopoietin; IL-18, interleukin-18; FABP3, fatty acid binding
protein; PPY, pancreatic polypeptide Y; I309, chemokine I309; SAA,
serum amyloid A; CRP, C-reactive protein; sVCAM, soluble vascular
adhesion molecule; sICAM, soluble intercellular adhesion molecule;
A2M, alpha-2-macroglobulin; B2M, beta-2 microglobulin; FVII, Factor
VII; adipo, adiponectin; apoJ, apolipoprotein J.

effective treatment, early diagnosis of AD is essential. However, apart from amyloid imaging, there are no established
blood biomarkers for AD. Many biomarkers reported in
the literature were limited by cohorts that were not characterized specifically for AD or were the result of crosssectional studies. Blood-based biomarkers are considered
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by many as a significant step forward to improve diagnostic
specificity and as a bridge between potential interventions
and monitoring of the disease progression.
The current selection of biomarkers has been highlighted
by previous work and warranted validation as to their usefulness. In this regard, we have measured their changes in the
participants of the well characterized AIBL cohort where
cognitive and lifestyle characteristics of each participant
are well documented and may be compared. This work
was undertaken to set the stage for a programmatic line of
work seeking to identify biomarkers of potential relevance
to predicting risk for future AD and current clinical diagnosis. Although the results from the current are internally
and not externally validated, the biomarkers investigated
were chosen on the basis that they had previously shown
some association with AD, thus by assessing each of the
markers in a large and well-characterized cohort, we have
been able to contribute to the evidence base defining their
potential use in AD prediction and diagnosis. The current
work clearly identifies signals across multiple plasmabased biomarkers that warrant further investigation and
shows that many markers are not validated after adjustment
for disease-modifying confounders.
Initial cross-sectional analysis of our data with proportional odds logistic regression revealed that 11 of the 14 tested
analyte levels changed over the 36 months between HC, MCI,
and AD before adjustment for covariates and multiple
comparisons. The analytes that demonstrated no change
were IL-18, CRP, and FVII. After accounting for the influences of age, sex, APOE genotype, and site with the generalized linear model statistical method, we found that the apoJ
and I309 levels are raised in AD category compared with
HC and MCI participants, respectively, at each of the baseline, 18- and 36-month sample times. This suggests that these
molecules might be affected or even have direct roles in the
brain as it undergoes pathological changes.
ApoJ, also known as clusterin, was initially discovered
over 20 years ago as a molecule which causes some testicular cells and erythrocytes to cluster and aggregate [24]. It
appears to be associated with apoptosis in tissues that
have been injured or undergoing regression or involution
[25–29]; however, its pathological significance remains
unclear. Determining the primary function of apoJ is
complicated by its propensity to interact with a range of
molecules, including itself [30]. It has been thought of as
an extracellular heat shock protein due to the presence of
a heat shock DNA element in its promoter region [31]. It
behaves much like an extracellular version of small heat
shock proteins that chaperone misfolded proteins to remain
soluble [32]. Its expression is upregulated in many
processes including development [33], response to injury
and stress, apoptosis [34,35], and neurodegeneration [36].
Therefore, it is no surprise that we find apoJ to be significantly increased in our AD participants compared with
their HC counterparts in all of the assessment periods. On
examination of apoJ, when the status of participants transits
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from HC to MCI or AD, it appears that this analyte does not
change markedly. These results suggest that apoJ, as
measured in the current protocols, may be most relevant
to the specific COU of detecting AD and perhaps monitoring progression within AD rather than the COU of
predicting future risk of AD although more work is needed.
In human plasma, this molecule is carried as a component
of high density lipoprotein (HDL) [37,38]. As a molecule in
the brain, it exists as a lower molecular weight form [39]
that is bound to HDL particles [40]. It has been identified in
noncovalent reversible complexes with soluble Ab and
some evidence suggests that it might cross the blood-brain
barrier [41,42]. The molecular weight differences between
liver-derived plasma apoJ and the astrocyte-derived form in
the brain are likely due to variation in glycosylation between
these two compartments.
This may be of functional significance for the AD brain
because intracellular forms of apoJ lack glycosylation [43]
before secretion and also appear to lack chaperone activity
[44]. These characteristics coupled with its ability to bind
a variety of molecules has led to the theory that secreted
apoJ is a molecular chaperone for extracellular misfolded
proteins [45–47]. There has been speculation that apoJ
might be a physiological carrier of Ab, and indeed, there
is evidence showing a reduction of Ab toxicity through its
sequestrating action [48]. Because of this, interest in posttranslational modification of apoJ has expanded. Although
it is known that differentially modified forms of apoJ are
made by different tissues [39,49], the significance of these
modifications are slowly being discovered [50].
Altered levels of apoJ are not only important for AD
[51–53], but also for other conditions [54,55], some of
which are linked to metabolic syndrome [56–60], another
risk factor for AD. It would be interesting to investigate
the altered apoJ levels observed between the AD and
healthy participants over time in light of posttranslational modifications. Further monitoring of our
cohort is still ongoing to gather more conclusive data.
ApoJ may yet be a useful early monitoring tool in combination with other biomarkers for cases of suspected AD.
PPY also demonstrated differences when examining our
data in those participants whose clinical status was AD.
This applied for all three periodic assessments, where the
AD group exhibited higher levels of PPY compared with
HC. This molecule has been identified in previous bloodbased biomarker investigations [3,8,9,61,62] as being
associated with MCI and AD but its role is currently
unclear. PPY is a small signaling molecule secreted by PP
cells at the periphery of Islets of Langerhans within the
pancreas and released into the circulation after a meal
[63]. The most widely accepted function for PPY is the regulation of postprandial appetite suppression via actions on the
gastrointestinal tract and brain [64] via the Y4 and Y5 neuropeptide receptors which initiate vagal signaling [65,66].
However, it has also been shown to control other
pancreatic secretions [67–71]. An impaired feeding

induced response from the gut that produces low levels of
PPY is associated with obesity and hyperphagia [72,73],
whereas excess PPY results in weight loss [74]. In the
AIBL cohort, the AD participants have lower average weight
[16], suggesting that an overproduction of PPY might be a
factor. This could arise from an over stimulation of the vagal
nerve [75]. Interestingly, vagal nerve stimulation was once
considered as a treatment for AD [76] because of previously
observed improvements in cognition and depression from
this treatment [77,78]. This suggests that increased PPY
may have relationship with dietary physiology and might
be a response to AD brain pathology hence is most likely
relevant for COU of AD diagnosis.
Adipo is a protein hormone which has come to light due
to its connection with antiobesity [79] and neuroprotective
effects. It regulates many functions including inflammatory
response [80], food intake, glucose regulation [81], and fatty
acid catabolism in the periphery. It is secreted into the circulation by adipose tissue as a collection of full-length species
ranging up to trimeric and larger species and even globular
form. Indeed, low levels of adipo are considered a risk factor
for metabolic syndrome [82], which itself is a risk factor for
AD. In our cohort, increased adipo levels were seen in the
AD participants over their HC counterparts at baseline and
36-month sampling periods. This increase is consistent
with previous work [83,84] which also shows that there is
some correlation in CSF. Although the 18-month period
showed a similar trend, this might suggest that the alteration
is a gradual process in response to changing brain pathology.
This may also be a response to neuroinflammation because it
is a relatively abundant anti-inflammatory adipokine which
concomitantly reduces expression of proinflammatory
cytokines [85] while increasing anti-inflammatory cytokines
[86]. This work suggests that adipo may be of most use in the
specific COU of AD diagnostics.
Among the biomarkers tested in the transition from MCI
to AD, chemokine I-309 (CCL1) was found to show the most
significant changes. This is consistent with previous work in
CSF where it was associated with cognitive decline [1] and
in other biomarker panels [9,87]. This molecule is a
glycoprotein that is secreted by activated T-lymphocytes
[88,89] and is related to a class of inflammatory cytokines
that carry the C-C motif. Its primary function appears to
be to attract monocytes, natural killer cells, immature B
cells, and dendritic cells, which all carry the necessary
CCR8 receptor [90]. It also elicits activation of monocyte
intracellular calcium mobilization as part of the immune
response [89].
Generally, chemokines are produced locally at sites of
inflammation or infection to regulate recruitment of other
immune cells such as leukocytes and lymphocytes. The
consistent increase of I-309 in the MCI-AD transition participants could indicate increasing brain injury or pathology.
Chemokines are typically released by endothelial cells on
stimulation by inflammatory cytokines [91–93], but I-309
is unusual because it is released by the more mobile
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T-lymphocytes, which could suggest a wider immune
response from the body. One of the possible effects may
be to attract immune cells to injured areas, such as to help
clear away amyloid as seen in studies of the similar CCL2
receptor [94]. The current data suggest that plasma I-309
levels may be most useful in the COU of detecting AD
and distinguishing AD from MCI. Interestingly, we also
find it to be changed significantly in those who underwent
transition from MCI to AD over all three test periods. It is
possible that specific alterations of I-309 at specific time
points may also be indicative of imminent likelihood of
transition from MCI to AD.
sVCAM1 belongs to a class of cell adhesion molecules
(CAMs), binding proteins that appear to be important in
inflammatory or injury processes involving the endothelium
and blood cells, such as platelets. These soluble molecules
are generally present in the circulation near sites of injury to
the endothelium, such as an atherosclerotic plaque [95–99].
After cytokine activation, CAMS are released into the
circulation, which may then be detected. It has been
reported that measurement of these molecules could be
useful in diagnosis of cardiovascular injury [100–103].
When comparing the HC with AD participants, sVCAM
did not change markedly until 36 months in our study.
This delay might indicate that sVCAM might be a
reparatory physiological response to injury and
inflammation, rather than an initiator that directly
influences the pathology because it is upregulated in
endothelial cells that have been stimulated by cytokines
[104]. It mediates the adhesion of lymphocytes, monocytes,
eosinophils, and basophils to the vasculature [105,106] and
is implicated in the early stages of atherosclerosis [107].
This suggests that peripheral vascular injury contributes
to the pathology of the AD-affected brain. Further followup examinations of the cohort would help to shed more light
on the physiological processes involved.
There are significant advantages of the present study
over much prior work. First, the current work examined
longitudinal change in multiple previously identified potential AD blood-based biomarkers. In addition, the sample
size is significantly larger than much prior work and the
deep phenotypic characterization of the AIBL cohort is
an additional advantage. In the current work, multiple
biomarkers were examined longitudinally to identify a set
of markers for further examination in the COU of
diagnosing and predicting future risk of AD. In this
work, multiple markers were supported as potential diagnostic AD biomarkers while others were only likely useful
for future risk prediction. As was pointed out recently by
an international working group (including the current
team), the first step in moving biomarker discovery to
potential clinical use is the identification and initial support
of the biomarkers within the specific COU. The current
work addresses that first step and sets the stage for movement toward (1) additional replication of these biomarkers
(individually and in combination) as well as (2) discovery
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of additional biomarkers of relevance to this specific COU.
The AIBL cohort provides a unique cohort for these next
steps, which will then be replicated across independent
cohorts.
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RESEARCH IN CONTEXT

1. Systematic review: Blood biomarkers have attracted
a great deal of attention in recent times in regards to
early diagnosis and monitoring of Alzheimer’s disease (AD); however, there is a huge inconsistency
in the field.
2. Interpretation: We have used plasma samples from
the Australian Imaging, Biomarkers and Lifestyle
(AIBL) Study of Ageing cohort to specifically
answer the question if plasma protein biomarkers
can be used for diagnostic accuracy. Our results
show that levels of I309 and PPY were significantly
increased in AD participants compared with MCI
participants over time. We also showed apolipoprotein J to be increased in AD patients compared
with healthy participants longitudinally.
3. Future directions: The current work addresses that
first step and sets the stage for movement towards
(1) additional replication of these biomarkers (individually and in combination) as well as (2) discovery
of additional biomarkers of relevance to this specific
COU. The AIBL cohort provides a unique cohort for
these next steps, which will then be replicated across
independent cohorts.
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